ERLEADA® (apalutamide) demonstrates statistically significant …
WEB1 day ago · The proportion of patients alive at 24 months (87.6 percent) observed in the ERLEADA ® cohort in this real-world analysis is consistent with that in the Phase 3 TITAN trial (82.4 percent). 1 ...
Johnson & Johnson's Erleada Shows Improved Overall Survival In …
WEB1 day ago · Wednesday, Johnson & Johnson (NYSE:JNJ) revealed results from a head-to-head study of Erleada (apalutamide) compared to Pfizer Inc’s (NYSE:PFE) Xtandi (enzalutamide). The data showed that ...
J&J’s Erleada provides survival edge over Astellas’ Xtandi
WEB1 day ago · The study looked at treatment outcomes for more than 3,700 patients and found that Erleada reduced the risk of death by 23% over Xtandi after 24 months, J&J said in a Tuesday release. The ...
ERLEADA demonstrates statistically significant and clinically ...
WEBThe proportion of patients alive at 24 months (87.6 percent) observed in the ERLEADA cohort in this real-world analysis is consistent with that in the Phase 3 TITAN trial (82.4 percent). 1 TITAN demonstrated a statistically significant superior overall survival benefit of ERLEADA plus androgen deprivation therapy (ADT) compared to ADT alone at ...
ERLEADA® (apalutamide) demonstrates statistically significant …
WEB1 day ago · The proportion of patients alive at 24 months (87.6 percent) observed in the ERLEADA ® cohort in this real-world analysis is consistent with that in the Phase 3 TITAN trial (82.4 percent). 1 TITAN demonstrated a statistically significant superior overall survival benefit of ERLEADA ® plus androgen deprivation therapy (ADT) compared to ADT ...
2024-10-02 | ERLEADA® (apalutamide) demonstrates statistically ...
WEB1 day ago · Largest head-to-head real-world study in mCSPC demonstrated that ERLEADA ® reduced risk of death by 23 percent at 24 months compared to enzalutamide. LISBON, Portugal, Oct. 2, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced the results of a landmark real-world, head-to-head study showing that ERLEADA ® (apalutamide) provided a statistically significant ...
Apalutamide associated with improved survival vs enzalutamide in …
WEB1 day ago · Apalutamide (Erleada) was found to be associated with a significant improvement in overall survival (OS) compared with enzalutamide (Xtandi) in the treatment of androgen receptor pathway inhibitor (ARPI)-naïve patients with metastatic castration-sensitive prostate cancer (mCSPC), according to data from a …
Phase 2 data for ERLEADA® (apalutamide) plus androgen …
WEBSAN ANTONIO, May 3, 2024 – Johnson & Johnson announced today results from the open-label, single-arm Phase 2 Apa-RP study evaluating adjuvant treatment with ERLEADA ® (apalutamide) and androgen deprivation therapy (ADT) in patients with HRLPC who have undergone radical prostatectomy (RP).
JNJ's Erleada Shows Statistically Significant Overall Survival In ...
WEB1 day ago · Health News. Johnson & Johnson (JNJ), Wednesday announced results from a head-to-head study, demonstrating statistically significant overall survival benefit in patients on Erleada at 24 months compared to Enzalutamide in patients with metastatic castration-sensitive prostate cancer.
Phase 2 data for ERLEADA® (apalutamide) plus androgen …
WEBMay 3, 2024 · Johnson & Johnson announced today results from the open-label, single-arm Phase 2 Apa-RP study evaluating adjuvant treatment with ERLEADA® (apalutamide) and androgen deprivation therapy (ADT) in...